These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 16796642

  • 1. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report.
    Zerpa O, Blanco B, Kannee C, Ulrich M, Sindermann H, Engel J, Convit J.
    Int J Dermatol; 2006 Jun; 45(6):751-3. PubMed ID: 16796642
    [Abstract] [Full Text] [Related]

  • 2. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y.
    Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
    [Abstract] [Full Text] [Related]

  • 3. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
    Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, Matos N, Mendoza I, Pratlong F, Ravel C, Convit J.
    Br J Dermatol; 2007 Jun; 156(6):1328-35. PubMed ID: 17441955
    [Abstract] [Full Text] [Related]

  • 4. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ.
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [Abstract] [Full Text] [Related]

  • 5. [Miltefosine: a new remedy for leishmaniasis].
    Dorlo TP, Eggelte TA, Beijnen JH, de Vries PJ.
    Ned Tijdschr Geneeskd; 2006 Dec 09; 150(49):2697-701. PubMed ID: 17194005
    [Abstract] [Full Text] [Related]

  • 6. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J.
    Clin Infect Dis; 2001 Oct 01; 33(7):E57-61. PubMed ID: 11528586
    [Abstract] [Full Text] [Related]

  • 7. Miltefosine for new world cutaneous leishmaniasis.
    Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H.
    Clin Infect Dis; 2004 May 01; 38(9):1266-72. PubMed ID: 15127339
    [Abstract] [Full Text] [Related]

  • 8. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.
    Am J Trop Med Hyg; 2009 Mar 01; 80(3):336-8. PubMed ID: 19270277
    [Abstract] [Full Text] [Related]

  • 9. Miltefosine in cutaneous leishmaniasis.
    Rahman SB, ul Bari A, Mumtaz N.
    J Coll Physicians Surg Pak; 2007 Mar 01; 17(3):132-5. PubMed ID: 17374296
    [Abstract] [Full Text] [Related]

  • 10. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V, Ansari NA, Jain RK, Salotra P.
    Clin Exp Dermatol; 2008 Jan 01; 33(1):103-5. PubMed ID: 17979988
    [No Abstract] [Full Text] [Related]

  • 11. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
    Ruiz-Villaverde R, Sánchez-Cano D, Villaverde-Gutierrez C.
    J Eur Acad Dermatol Venereol; 2007 May 01; 21(5):695-6. PubMed ID: 17447994
    [No Abstract] [Full Text] [Related]

  • 12. Successful treatment of a married couple for American leishmaniasis with miltefosine.
    Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A.
    J Eur Acad Dermatol Venereol; 2008 Feb 01; 22(2):258-9. PubMed ID: 18211436
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Miltefosine for disseminated cutaneous leishmaniasis].
    González LM, Vélez ID.
    Biomedica; 2006 Oct 01; 26 Suppl 1():13-6. PubMed ID: 17361837
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A.
    Acta Trop; 2007 Jul 01; 103(1):33-40. PubMed ID: 17586452
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
    Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, Grimm F, Mathis A, Weber R, Günthard HF.
    Clin Infect Dis; 2005 Jun 15; 40(12):e120-4. PubMed ID: 15909255
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W, Eibl HJ, Engel KR, Kuhlencord A, Sindermann H, Sundar S, Zappel H.
    Wien Klin Wochenschr; 2004 Jun 15; 116 Suppl 4():24-9. PubMed ID: 15683039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.